MELD Score: Liver Disease Severity, Transplant Priority & Prognosis | RxMedCalc
The MELD and MELD-Na formulas, 90-day mortality by score, liver transplant waitlist prioritisation, MELD in alcoholic hepatitis and acute liver failure, and comparison with Child-Pugh.
Chronic liver disease and cirrhosis affect millions of people worldwide — in India, liver disease is one of the top 10 causes of death, driven by viral hepatitis B and C, alcohol-related liver disease, and increasingly, non-alcoholic fatty liver disease (NAFLD/MASLD). When cirrhosis progresses to decompensated liver failure, the question that haunts every clinical decision is: how sick is this patient, and how urgently do they need a transplant?
The Model for End-Stage Liver Disease (MELD) score answers this question with mathematical precision. Derived from three laboratory values — bilirubin, creatinine, and INR — MELD predicts 90-day mortality in patients with end-stage liver disease and is the foundation of liver transplant allocation worldwide.
The MELD Formula
+ 11.2 × ln[INR]
+ 9.57 × ln[Creatinine (mg/dL)]
+ 6.43
Minimum values: Bilirubin ≥ 1.0, INR ≥ 1.0, Creatinine ≥ 1.0 (set all values below 1.0 to 1.0)
Maximum creatinine: 4.0 mg/dL (cap if on dialysis or creatinine > 4.0)
Score rounded to nearest whole number. Maximum score used in transplant: 40.
Na = Serum sodium (mEq/L). Cap Na at 125 (minimum) and 137 (maximum) before calculating.
MELD-Na better predicts 90-day waitlist mortality and is now the UNOS transplant allocation standard.
🫀 Use the RxMedCalc MELD Score Calculator — calculates both MELD and MELD-Na with 90-day mortality prediction and transplant priority guidance.
MELD Score and 90-Day Mortality
| MELD Score | 90-Day Mortality | Clinical Implication |
|---|---|---|
| < 10 | < 5% | Low short-term mortality. Outpatient management typically appropriate. Re-evaluate trigger for hospitalisation. |
| 10–14 | ~10% | Moderate risk. Close outpatient follow-up or hospitalisation based on clinical context. |
| 15–19 | ~20% | Significant risk. Transplant evaluation should begin. Hospitalisation often warranted. |
| 20–29 | ~40–50% | High risk. Active transplant listing. Aggressive management of complications. |
| 30–39 | ~55–70% | Very high risk. Urgent transplant priority. ICU-level care. |
| ≥ 40 | > 80% | Critically high. Highest transplant priority. Consider palliative goals if transplant not possible. |
Why MELD Uses These Three Variables
The three components of MELD each reflect a specific aspect of liver failure's systemic consequences:
- Bilirubin — reflects the liver's ability to conjugate and excrete waste. Rising bilirubin indicates failing hepatocellular function and is the most visible marker of hepatic decompensation.
- INR (International Normalised Ratio) — reflects coagulation factor synthesis. The liver produces all clotting factors except Factor VIII. A rising INR indicates severe hepatocellular dysfunction and predicts bleeding complications.
- Creatinine — reflects renal function. The kidneys are intimately linked to liver failure — hepatorenal syndrome (HRS), where renal failure occurs as a direct consequence of advanced cirrhosis, carries very high mortality. Elevated creatinine in a cirrhotic patient is an ominous sign.
Notably, MELD does not include clinical signs like ascites, encephalopathy, or jaundice — it is entirely laboratory-based, making it objective and reproducible across settings.
Why Sodium Was Added — MELD-Na
Hyponatraemia (low serum sodium) is a powerful independent predictor of mortality in cirrhosis, not captured by the original MELD. Sodium below 130 mEq/L in a cirrhotic patient indicates severe portal hypertension with massive sodium retention and is associated with high 90-day mortality even at moderate MELD scores.
MELD-Na incorporates serum sodium to correct for this. Two patients with an identical MELD of 18 — one with sodium 138 and one with sodium 126 — have very different prognoses. MELD-Na correctly assigns the hyponatraemic patient a higher score, prioritising them appropriately on transplant waitlists. UNOS (United States) adopted MELD-Na as the transplant allocation standard in 2016.
MELD in Specific Clinical Scenarios
Alcoholic Hepatitis
Severe alcoholic hepatitis — defined as Maddrey's Discriminant Function > 32 or MELD > 20 — carries very high short-term mortality (30–40% at 30 days without treatment). In severe alcoholic hepatitis, MELD is used to:
- Identify patients likely to benefit from prednisolone therapy (MELD 20–54 with no active infection or GI bleeding)
- Monitor response to treatment — a fall in MELD at day 7 (Lille score) predicts response; failure to respond indicates consideration of early liver transplantation in carefully selected abstinent patients
Acute-on-Chronic Liver Failure (ACLF)
ACLF — acute decompensation of cirrhosis triggered by a precipitating event (infection, GI bleed, alcohol binge) — is associated with much higher short-term mortality than the MELD alone predicts, because of multi-organ failure. The CLIF-C ACLF score (incorporating organ failure grading) is preferred in ACLF, but MELD remains a useful baseline severity measure.
Acute Liver Failure (ALF)
In acute liver failure (e.g. paracetamol overdose, viral hepatitis B fulminant failure, drug-induced liver injury), MELD is used alongside the King's College Criteria to guide emergency transplant listing. MELD > 30 in ALF is a marker of poor prognosis without transplantation.
MELD vs Child-Pugh Score
| Feature | MELD / MELD-Na | Child-Pugh |
|---|---|---|
| Variables | Bilirubin, INR, Creatinine (± Na) | Bilirubin, albumin, PT/INR, ascites, encephalopathy |
| Objective? | Entirely laboratory-based — fully objective | Includes subjective clinical grading of ascites and encephalopathy |
| Mortality prediction | Better for short-term (90-day) mortality | Better for medium-term (1–2 year) prognosis |
| Transplant allocation | Standard tool — used by UNOS, Eurotransplant | Not used for allocation — superseded by MELD |
| Best use | Transplant prioritisation, acute decompensation severity | General cirrhosis severity staging, surgical risk |
Common Causes of Liver Disease in India
India's liver disease burden has a different aetiology profile from Western countries, which affects MELD use in practice:
- Hepatitis B: India has ~40 million chronic HBV carriers. HBV cirrhosis is the leading cause of hepatocellular carcinoma (HCC) in India. MELD guides timing of antiviral therapy escalation and transplant listing.
- Hepatitis C: ~6 million HCV-infected individuals. Direct-acting antiviral (DAA) therapy can dramatically improve MELD in compensated cirrhosis — a post-SVR MELD reduction is now a recognised phenomenon requiring waitlist reassessment.
- Alcohol-related liver disease: Rising rapidly, particularly in urban India. Alcoholic hepatitis is a major cause of acute MELD elevation.
- NAFLD/MASLD: Increasing in parallel with the diabetes and obesity epidemic. India has among the highest NAFLD prevalence in Asia.
- Budd-Chiari syndrome: More common in India than in Western countries — often presents acutely with very high MELD requiring urgent anticoagulation and/or transplant consideration.
Key Takeaways
- MELD uses bilirubin, INR, and creatinine to predict 90-day mortality in end-stage liver disease
- MELD-Na adds serum sodium — better predicts waitlist mortality and is the current UNOS transplant allocation standard
- MELD < 10 = low short-term risk; MELD ≥ 20 = high risk warranting transplant evaluation; MELD ≥ 30 = very high urgency
- Set all input values to a minimum of 1.0; cap creatinine at 4.0 mg/dL (or set to 4.0 if on dialysis)
- MELD is entirely objective (laboratory-based) — superior to Child-Pugh for acute severity and transplant allocation
- Severe alcoholic hepatitis: MELD > 20 indicates consideration of prednisolone therapy
- India's dominant causes: Hepatitis B, alcohol, and rising NAFLD — all assessed with MELD for transplant and prognosis decisions
References
- Kamath PS et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-470.
- Kim WR et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med. 2008;359(10):1018-1026.
- AASLD. Liver Transplantation Practice Guideline. Hepatology. 2023.
- EASL. Clinical Practice Guidelines on Decompensated Cirrhosis. J Hepatol. 2018;69(2):406-460.
- Sarin SK et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 2019.
This article is for educational purposes based on AASLD and EASL guidelines. MELD score interpretation and liver transplant decisions must be made by a qualified hepatologist or transplant physician.
Built by an MBBS, AFIH Certified Physician in Punjab, India | RxMedCalc.com